Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/BCL10_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/BCL10_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BCL10_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/BCL10_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BCL10_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/BCL10_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/BCL10_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BCL10_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00027646 | Oral cavity | OSCC | immune response-regulating signaling pathway | 212/7305 | 468/18723 | 2.93e-03 | 1.27e-02 | 212 |
GO:0070227 | Oral cavity | OSCC | lymphocyte apoptotic process | 40/7305 | 72/18723 | 3.21e-03 | 1.38e-02 | 40 |
GO:20001061 | Oral cavity | OSCC | regulation of leukocyte apoptotic process | 44/7305 | 81/18723 | 3.66e-03 | 1.51e-02 | 44 |
GO:005087010 | Oral cavity | OSCC | positive regulation of T cell activation | 104/7305 | 216/18723 | 3.76e-03 | 1.55e-02 | 104 |
GO:00605629 | Oral cavity | OSCC | epithelial tube morphogenesis | 149/7305 | 325/18723 | 6.73e-03 | 2.50e-02 | 149 |
GO:00508564 | Oral cavity | OSCC | regulation of T cell receptor signaling pathway | 24/7305 | 41/18723 | 8.81e-03 | 3.19e-02 | 24 |
GO:0002902 | Oral cavity | OSCC | regulation of B cell apoptotic process | 13/7305 | 19/18723 | 9.07e-03 | 3.26e-02 | 13 |
GO:0002903 | Oral cavity | OSCC | negative regulation of B cell apoptotic process | 9/7305 | 12/18723 | 1.27e-02 | 4.24e-02 | 9 |
GO:00027022 | Oral cavity | OSCC | positive regulation of production of molecular mediator of immune response | 58/7305 | 117/18723 | 1.28e-02 | 4.27e-02 | 58 |
GO:2001233110 | Oral cavity | LP | regulation of apoptotic signaling pathway | 168/4623 | 356/18723 | 1.35e-20 | 3.02e-18 | 168 |
GO:0045862110 | Oral cavity | LP | positive regulation of proteolysis | 165/4623 | 372/18723 | 5.40e-17 | 8.46e-15 | 165 |
GO:2000116110 | Oral cavity | LP | regulation of cysteine-type endopeptidase activity | 109/4623 | 235/18723 | 3.16e-13 | 2.91e-11 | 109 |
GO:1903320110 | Oral cavity | LP | regulation of protein modification by small protein conjugation or removal | 111/4623 | 242/18723 | 4.81e-13 | 4.30e-11 | 111 |
GO:0043281110 | Oral cavity | LP | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 99/4623 | 209/18723 | 7.89e-13 | 6.68e-11 | 99 |
GO:004312316 | Oral cavity | LP | positive regulation of I-kappaB kinase/NF-kappaB signaling | 88/4623 | 186/18723 | 1.58e-11 | 1.13e-09 | 88 |
GO:0052547110 | Oral cavity | LP | regulation of peptidase activity | 177/4623 | 461/18723 | 3.01e-11 | 2.00e-09 | 177 |
GO:0031396110 | Oral cavity | LP | regulation of protein ubiquitination | 95/4623 | 210/18723 | 5.88e-11 | 3.61e-09 | 95 |
GO:0052548110 | Oral cavity | LP | regulation of endopeptidase activity | 164/4623 | 432/18723 | 4.33e-10 | 2.20e-08 | 164 |
GO:0010952110 | Oral cavity | LP | positive regulation of peptidase activity | 88/4623 | 197/18723 | 6.52e-10 | 3.14e-08 | 88 |
GO:200123518 | Oral cavity | LP | positive regulation of apoptotic signaling pathway | 63/4623 | 126/18723 | 7.17e-10 | 3.43e-08 | 63 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BCL10 | SNV | Missense_Mutation | novel | c.276G>T | p.Gln92His | p.Q92H | O95999 | protein_coding | deleterious(0.02) | probably_damaging(0.969) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BCL10 | SNV | Missense_Mutation | | c.262C>G | p.Arg88Gly | p.R88G | O95999 | protein_coding | deleterious(0.01) | probably_damaging(0.945) | TCGA-C8-A1HK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BCL10 | SNV | Missense_Mutation | | c.682N>T | p.Arg228Cys | p.R228C | O95999 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
BCL10 | SNV | Missense_Mutation | novel | c.256N>C | p.Ile86Leu | p.I86L | O95999 | protein_coding | deleterious(0.04) | possibly_damaging(0.56) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
BCL10 | insertion | Frame_Shift_Ins | rs387906351 | c.136_137insA | p.Ile46AsnfsTer4 | p.I46Nfs*4 | O95999 | protein_coding | | | TCGA-D8-A140-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin+cyclophosphamid | SD |
BCL10 | SNV | Missense_Mutation | | c.682N>T | p.Arg228Cys | p.R228C | O95999 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-VS-A957-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BCL10 | SNV | Missense_Mutation | novel | c.415N>A | p.Asp139Asn | p.D139N | O95999 | protein_coding | tolerated(0.46) | benign(0) | TCGA-XS-A8TJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
BCL10 | SNV | Missense_Mutation | | c.322A>C | p.Asn108His | p.N108H | O95999 | protein_coding | tolerated(0.06) | possibly_damaging(0.707) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
BCL10 | SNV | Missense_Mutation | novel | c.200N>C | p.Lys67Thr | p.K67T | O95999 | protein_coding | tolerated(0.17) | probably_damaging(0.951) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BCL10 | SNV | Missense_Mutation | | c.235N>A | p.Leu79Met | p.L79M | O95999 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |